US Food and Drug Administration. Human gene therapy for rare diseases: guidance for industry. Rockville, MD: US Food and Drug Administration; 2020. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-gene-therapy-rare-diseases. Accessed 2025 Jul 1.

Benjamin K, Vernon MK, Patrick DL, Perfetto E, Nestler-Parr S, Burke L. Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report. Value Health. 2017;20(7):838–55. https://doi.org/10.1016/j.jval.2017.05.015.

Article  PubMed  Google Scholar 

Deal LS, Goldsmith JC, Martin S, Barbier AJ, Roberds SL, Schubert DH. Patient voice in rare disease drug development and endpoints. Ther Innov Regul Sci. 2017;51(2):257–63. https://doi.org/10.1177/2168479016671559.

Article  PubMed  Google Scholar 

US Food and Drug Administration. Rare diseases: considerations for the development of drugs and biological products. Rockville, MD: US Food and Drug Administration; 2023. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/rare-diseases-considerations-development-drugs-and-biological-products. Accessed 2025 Jul 1.

US Food and Drug Administration. FDA patient-focused drug development guidance series for enhancing the incorporation of the patient’s voice in medical product development and regulatory decision making. Rockville, MD: US Food and Drug Administration; 2025. https://www.fda.gov/drugs/development-approval-process-drugs/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Accessed 2025 Jul 1.

US Food and Drug Administration. Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. Silver Spring, MD: US Food and Drug Administration; 2023. https://www.fda.gov/media/166830/download. Accessed 2025 Jul 1.

European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. London: European Medicines Agency; 2018. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-quality-non-clinical-and-clinical-aspects-gene-therapy-medicinal-products_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Cellular & gene therapy guidances. Silver Spring, MD: US Food and Drug Administration; 2023. https://www.fda.gov/vaccines-blood-biologics/biologics-guidances/cellular-gene-therapy-guidances. Accessed 2025 Jul 1.

US Food and Drug Administration. FDA approval brings first gene therapy to the United States. Silver Spring, MD: US Food and Drug Administration; 2017. https://web.archive.org/web/20170831030039/https:/www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm. Accessed 2025 Jul 1.

Tandulje AA, Varpe PC, Chaugule PD, et al. Cell and gene therapy products: navigating the regulatory landscape of paradigm approvals in the US (2020 to 2024). J Pharm Innov. 2025;20:63. https://doi.org/10.1007/s12247-025-09973-8.

Article  Google Scholar 

US Food and Drug Administration. Considerations for the design of early-phase clinical trials of cellular and gene therapy products: guidance for industry. Rockville, MD: US Food and Drug Administration; 2015. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-design-early-phase-clinical-trials-cellular-and-gene-therapy-products. Accessed 2025 Jul 1.

Toro W, Yang M, Patel A, Zhang S, Dabbous O, Garrison LP Jr. Evolving concept of value in health economics and outcomes research: emerging tools for innovation and access to cell and gene therapies for rare diseases. Value Health. 2025;28(5):686–91. https://doi.org/10.1016/j.jval.2024.12.006.

Article  PubMed  Google Scholar 

Shen J, Swift B, Mamelok R, Pine S, Sinclair J, Attar M. Design and conduct considerations for first-in-human trials. Clin Transl Sci. 2019;12(1):6–19. https://doi.org/10.1111/cts.12582.

Article  PubMed  Google Scholar 

Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp Clin Trials Commun. 2018;11:156–64. https://doi.org/10.1016/j.conctc.2018.08.001.

Article  PubMed  PubMed Central  Google Scholar 

Fabre A, Guerry P. Goldilocks principle and recessive disease. Eur J Hum Genet. 2024;32:143–5. https://doi.org/10.1038/s41431-023-01458-x.

Article  PubMed  Google Scholar 

US Food and Drug Administration. Long term follow-up after administration of human gene therapy products: guidance for industry. Silver Spring, MD: US Food and Drug Administration; 2020. https://www.fda.gov/media/113768/download. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Zolgensma. Silver Spring, MD: US Food and Drug Administration; 2019. https://www.fda.gov/media/127961/download?attachment. Accessed 2025 Jul 1.

European Medicines Agency. Orphan maintenance assessment report for Zolgensma. Amsterdam: European Medicines Agency; 2020. https://www.ema.europa.eu/en/documents/orphan-maintenance-report/zolgensma-orphan-maintenance-assessment-report-initial-authorisation_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Lenmeldy. Silver Spring, MD: US Food and Drug Administration; 2024. https://www.fda.gov/media/177578/download?attachment. Accessed 2025 Jul 1.

European Medicines Agency. Orphan maintenance assessment report for Libmeldy. Amsterdam: European Medicines Agency; 2020. https://www.ema.europa.eu/en/documents/orphan-maintenance-report/libmeldy-orphan-maintenance-assessment-report-initial-authorisation_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Kebilidi. Silver Spring, MD: US Food and Drug Administration; 2024. https://www.fda.gov/media/184353/download. Accessed 2025 Jul 1.

European Medicines Agency. Orphan maintenance assessment report for Upstaza (eladocagene exuparvovec). Amsterdam: European Medicines Agency; 2022. https://www.ema.europa.eu/en/documents/orphan-maintenance-report-post/upstaza-epar-orphan-maintenance-assessment-report_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Skysona. Silver Spring, MD: US Food and Drug Administration; 2022. https://www.fda.gov/media/162098/download?attachment. Accessed 2025 Jul 1.

European Medicines Agency. Assessment report for Strimvelis. London: European Medicines Agency; 2016. https://www.ema.europa.eu/en/documents/assessment-report/strimvelis-epar-public-assessment-report_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Zynteglo. Silver Spring, MD: US Food and Drug Administration; 2022. https://www.fda.gov/media/161472/download?attachment. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Roctavian. Silver Spring, MD: US Food and Drug Administration; 2023. https://www.fda.gov/media/170455/download?attachment. Accessed 2025 Jul 1.

European Medicines Agency. Assessment report for Roctavian. Amsterdam: European Medicines Agency; 2022. https://www.ema.europa.eu/en/documents/assessment-report/roctavian-epar-public-assessment-report_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Hemgenix. Silver Spring, MD: US Food and Drug Administration; 2022. https://www.fda.gov/media/164094/download. Accessed 2025 Jul 1.

European Medicines Agency. Hemgenix (etranacogene dezaparvovec). Amsterdam: European Medicines Agency; 2023. https://www.ema.europa.eu/en/documents/overview/hemgenix-epar-medicine-overview_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Luxturna. Silver Spring, MD: US Food and Drug Administration; 2017. https://www.fda.gov/files/vaccines%2C%20blood%20%26%20biologics/published/December-18--2017-Summary-Basis-for-Regulatory-Action---LUXTURNA.pdf. Accessed 2025 Jul 1.

European Medicines Agency. Luxturna (voretigene neparvovec). London: European Medicines Agency; 2018. https://www.ema.europa.eu/en/documents/overview/luxturna-epar-medicine-overview_en.pdf. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Elevidys. Silver Spring, MD: US Food and Drug Administration; 2023. https://www.fda.gov/media/169746/download. Accessed 2025 Jul 1.

US Food and Drug Administration. Summary basis for regulatory action for Vyjuvek. Silver Spring, MD: US Food and Drug Administration; 2023. https://www.fda.gov/media/169342/download. Accessed 2025 Jul 1.

Pharmaceuticals and Medical Devices Agency. Report on the deliberation results for Collategene. Tokyo: Pharmaceuticals and Medical Devices Agency; 2019. https://www.pmda.go.jp/files/000231386.pdf. Accessed 2025 Jul 1.

Guide SV, Gonzalez ME, Bagci IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211–9. https://doi.org/10.1056/NEJMoa2206663.

Article  CAS  PubMed  Google Scholar 

Strauss KA, Farrar MA, Muntoni F, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III SPR1NT trial. Nat Med. 2022;28(7):1390–7. https://doi.org/10.1038/s41591-022-01867-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kolb SJ, Coffey CS, Yankey JW, et al. Natural history of infantile-onset spinal muscular atrophy. Ann Neurol. 2017;82(6):883–91. https://doi.org/10.1002/ana.25101.

Article  CAS  PubMed  PubMed Central  Google Scholar 

US Food and Drug Administration. Cellular, tissue, and gene therapies advisory committee meeting for elivaldogene autotemcel. Silver Spring, MD: US Food and Drug Administration; 2022. https://www.fda.gov/media/159010/download

Vaghela S, Tanni KA, Banerjee G, Sikirica V. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases. Orphanet J Rare Dis. 2024;19(1):117. https://doi.org/10.1186/s13023-024-03111-2.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence. Eladocagene exuparvovec for treating aromatic l-amino acid decarboxylase deficiency. London: National Institute for Health and Care Excellence; 2023. https://www.nice.org.uk/guidance/hst26/resources/eladocagene-exuparvovec-for-treating-aromatic-lamino-acid-decarboxylase-deficiency-pdf-50216322673861. Accessed 2025 Jul 1.

Fumagalli F, Calbi V, Natali Sora MG, et al. Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access. Lancet. 2022;399(10322):372–83. https://doi.org/10.1016/S0140-6736(21)02017-1.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Eichler F, Duncan CN, Musolino PL, et al. Lentiviral gene therapy for cerebral adrenoleukodystrophy. N Engl J Med. 2024;391(14):1302–12. https://doi.org/10.1056/NEJMoa2400442.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Skysona (elivaldogene autotemcel). Prescribing information. bluebird bio, Inc; 2022.

Fahim SM, Lin G, Suh K, et al. Atidarsagene autotemcel for metachromatic leukodystrophy. J Manag Care Spec Pharm. 2024;30(2):201–5. https://doi.org/10.18553/jmcp.2024.30.2.201.

Article  PubMed  PubMed Central  Google Scholar 

Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013–25. https://doi.org/10.1056/NEJMoa2113708.

Article  CAS  PubMed  Google Scholar 

Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with etranacogene dezaparvovec for hemophilia B. N Engl J Med. 2023;388(8):706–18. https://doi.org/10.1056/NEJMoa2211644.

Article  CAS  PubMed  Google Scholar 

Locatelli F, Thompson AA, Kwiatkowski JL, et al. Betibeglogene autotemcel gene therapy for non-β0/β0 genotype β-thalassemia. N Engl J Med. 2022;386(5):415–27. https://doi.org/10.1056/NEJMoa2113206.

Article  CAS  PubMed  Google Scholar 

Fu K, Lawson-Michod K, Goodman M, Lally C, Ojodu J. Estimated prevalence of β-thalassemia in the United States in 2023. Poster presented at: 66th ASH Annual Meeting; December 7–10, 2024; San Diego, CA. Abstract 1098.

Mehta P, Reddivari AKR. Hemophilia. Treasure Island, FL: StatPearls; 2024. https://www.ncbi.nlm.nih.gov/books/NBK551607/. Accessed 2025 Jul 1.

Njeim R, Naouss B, Bou-Fakhredin R, Haddad A, Taher A. Unmet needs in β-thalassemia and the evolving treatment landscape. Transfus Clin Biol. 2024;31(1):48–55. https://doi.org/10.1016/j.tracli.2023.12.003.

Article  CAS  PubMed  Google Scholar